Both Male and Female ages 1 Month to 17 Years
C0168Z02 - Confirmed diagnosis of Crohn's disease, Ulcerative Colitis, or Indeterminate
Colitis for at least 2 months The parent/legal guardian must be capable of providing
written informed consent, and assent should be obtained from the child according to local
regulations (age at which assent is given may vary by the IRB or EC).
The patient's physician expects the patient to be scheduled for a medical encounter
(and/or other direct contact) at least every 6 months, as part of their usual care, at the
time of enrollment.
REMICADEPIB4002 and REMICADEPIB4003: Confirmed diagnosis of Crohn's disease or Ulcerative
Colitis for at least 2 months
C0168Z02: 17 years of age or older, with the exception of patients who participated in the
Sponsor's conducted pediatric IBD clinical trials.
Have other Crohn's-like diseases that are associated with genetic diseases (eg, glycogen
The patient and parent/guardian are not able to adhere to the protocol requirements.
Are participating in any clinical trial for an investigational agent that is not
REMICADEPIB4002 and REMICADEPIB4003: Less than 6 years of age or 17 years of age or older.